JGene Biotechnology

JGene Biotechnology, also known as 晶准生物医学 (Jingzhun Biomedicine), is a high-tech enterprise established in 2018. The company is strategically located in the Greater Bay Area, with facilities in both the Haikexing Strategic Emerging Industry Park in Shenzhen and the Hong Kong Science Park. JGene focuses on the liquid biopsy sector, encompassing the entire lifecycle from research and development to product conversion, manufacturing, sales, and testing services for precision medicine.

The company's core mission is to provide comprehensive liquid biopsy solutions for the complete management of tumor diagnostics. This includes early diagnosis and screening, assisted diagnosis, and guidance for medication and real-time monitoring. Its product portfolio is built upon patented technologies for detecting tumor cells and genetic information, which assists clinicians in formulating optimal therapeutic strategies. JGene has developed its own automated circulating tumor cell (CTC) detection platform, which includes the CTC100 Cell Sorter and the CellViewer 100 Cell Recognizer; both have received NMPA and CE certifications. This platform leverages microfluidic technology to efficiently isolate CTCs from blood samples for downstream analysis.

Financially, JGene Biotechnology has secured strategic investments to fuel its growth. In July 2023, it received a strategic equity investment from the Taiping Hong Kong Insurance Science and Technology Innovation Fund, which is affiliated with the China Taiping Insurance Group. This partnership also led to a strategic alliance with Taiping P&C Insurance's Shenzhen branch to create integrated "service + insurance" health products. The company also completed a Seed funding round on February 21, 2022, led by Vinno Capital and Efung Capital. These financial injections are intended to accelerate the development of new products and expand the company's commercial capabilities. JGene has received several accolades, including being named a "Hong Kong Rising Star" by Deloitte in 2019 and being recognized as one of the Top 50 innovative biotech companies in the Guangdong-Hong Kong-Macao Greater Bay Area.

Keywords: liquid biopsy, oncology diagnostics, circulating tumor cells, CTC detection, precision medicine, cancer screening, tumor monitoring, genetic testing, molecular diagnostics, NMPA certified, CE certified, microfluidics, non-invasive testing, Shenzhen, Hong Kong Science Park, Greater Bay Area, JGene Biotechnology, 晶准生物医学, cancer diagnostics, personalized medicine